What are the best prophylactic drugs for migraine?

**EVIDENCE-BASED ANSWER**

**A/ Beta-blockers** without intrinsic sympathomimetic activity, amitriptyline, divalproex sodium/sodium valproate, and topiramate are the most effective drugs for preventing episodic migraine (strength of recommendation: A, multiple, well-designed, randomized controlled trials [RCTs]).

**Beta-blockers** with intrinsic sympathomimetic activity (acebutolol, alpenolol, oxprenolol, pindolol) appear to be ineffective for migraine prevention.4

**Amitriptyline works better than propranolol for some migraines**

Amitriptyline is the most often studied antidepressant and the only one with consistent support for efficacy in preventing migraine. A 1981 trial found amitriptyline to be more effective than propranolol in mixed migraine-tension-type headache, whereas propranolol was more effective for migraine alone.5

**Some support for fluoxetine, none for similar drugs**

Limited evidence exists for the use of fluoxetine, 20 mg daily. A small 1999 study of patients with migraine without aura found a 57% reduction in total pain index—a value based on pain intensity and hours of headache per month—with fluoxetine compared with an insignificant 31% reduction with placebo.6

No evidence from controlled trials supports the use of fluvoxamine, paroxetine, sertraline, phenelzine, venlafaxine, mirtazapine, trazodone, or bupropion.3

**Divalproex sodium, sodium valproate are effective**

Divalproex sodium and sodium valproate show strong, consistent evidence of efficacy; they may be particularly useful for patients with prolonged or atypical migraine aura.4 Initial studies of delayed-release divalproex at doses ranging from 500 to 1500 mg daily found...
that 44% of divalproex-treated patients reported a 50% reduction in migraine frequency, compared with 21% in the placebo group (number needed to treat [NNT]=4). A more recent study of the extended-release form of divalproex sodium demonstrated a 4-week reduction in headache rate to 1.2 from a baseline of 4.4, compared with a decrease of 0.6 for placebo (95% confidence interval [CI] of treatment difference, 0.2-1.2).8

Topiramate may decrease frequency as much as propranolol
Topiramate has significantly reduced the mean frequency of episodic migraine at doses of 100 to 200 mg daily and also improved secondary end points, including number of migraine days per month, use of acute medication, and daily activity. One study found that topiramate 100 mg daily had comparable efficacy to propranolol 160 mg daily; both drugs decreased monthly migraine frequency to 1.6 from a baseline of 4.9 with topiramate and 5.1 with propranolol (95% CI for the pair-wise difference of topiramate minus propranolol, −0.58 to 0.60).9

Anticonvulsants also reduce migraine frequency
A 2004 Cochrane review of anticonvulsant drugs for migraine prophylaxis found that anticonvulsants, as a class, reduce migraine frequency by about 1.3 attacks per 28 days when compared with placebo (based on 10 trials [N=902]). When analyzing data on relative frequency of migraines, data from 13 trials (N=1773) were combined and showed that anticonvulsants more than doubled the number of patients with a 50% or greater decrease in migraine frequency relative to placebo (relative risk=2.25; 95% CI, 1.79-2.84; NNT=3.9; 95% CI, 3.4-4.7).11

Other drugs to keep on your radar
Agents available in the United States that have at least limited evidence supporting their use to prevent episodic migraine include gabapentin, lisinopril, candesartan, memantine, riboflavin, magnesium, feverfew, coenzyme Q10, butterbur, and melatonin.

Drugs so far proved ineffective in preventing episodic migraine include clonidine, carbamazepine, clonazepam, vigabatrin, oxcarbazepine, zonisamide, lamotrigine, nifedipine, and acetazolamide. Botulinum toxin type A given by intramuscular injection in the head and neck region has demonstrated limited efficacy in chronic headache disorders, but doesn’t prevent episodic migraine.12

### TABLE

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propranolol</td>
<td>80-240 mg/d</td>
<td>May cause fatigue. When used in combination with rizatriptan, give a lower dose of rizatriptan.</td>
</tr>
<tr>
<td>Timolol</td>
<td>20-30 mg/d</td>
<td>As with propranolol, may cause fatigue. Avoid β-blockers in patients with asthma or Raynaud’s disease.</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>25-150 mg/d</td>
<td>Drowsiness, weight gain, and significant anticholinergic adverse events are common.</td>
</tr>
<tr>
<td>Divalproex sodium; Sodium valproate</td>
<td>500-1500 mg/d; 800-1500 mg/d</td>
<td>Side effects include nausea, drowsiness, weight gain, hair loss, and tremor. Hepatotoxicity, pancreatitis, and hyperammonemia have been reported rarely. Pregnancy category D.</td>
</tr>
<tr>
<td>Topiramate</td>
<td>100-200 mg/d</td>
<td>Paresthesia is the most common adverse event; fatigue, nausea, anorexia, and cognitive symptoms are less common. Carbonic anhydrase inhibition may cause metabolic acidosis. Acute myopia and angle closure glaucoma are rare events.</td>
</tr>
</tbody>
</table>

Amitriptyline is more effective than propranolol for mixed migraine-tension-type headache, whereas propranolol works better for migraine alone.
Family Medicine

The Department of Family Medicine at the Cleveland Clinic is seeking board certified/eligible Family Medicine Physicians for outpatient positions in our Family Health Centers located throughout the Cleveland area. The positions include the opportunity to teach medical students from the Cleveland Clinic Lerner College of Medicine, precept Family Medicine Residents and to participate in practice based research.

Cleveland Clinic is an equal opportunity employer and is committed to increasing the diversity of its faculty. It welcomes nominations of and applications from women and members of minority groups, as well as others who would bring additional dimensions to its research, teaching, and clinical missions. Cleveland Clinic is a smoke/drug free work environment.

Interested candidates should forward a current copy of their CV in WORD format to the attention of Joe Vitale, Senior Director, Office of Physician Recruitment, Professional Staff Affairs; vitalej@ccf.org or apply online at www.ccf.org

CLINICAL INQUIRIES

Recommendations

The 2000 guidelines of the American Association of Neurology address Group 1 (first-line) drugs and Group 2 drugs:

- **Group 1 drugs** (medium to high efficacy, good strength of evidence, and a range of severity [mild to moderate] and frequency [infrequent to frequent] of side effects) include amitriptyline, divalproex sodium, propranolol, and timolol.

- **Group 2 drugs** (lower efficacy than Group 1, or limited strength of evidence, and mild to moderate side effects) include aspirin (but not combination products), atenolol, fenoprofen, feverfew, flurbiprofen, fluoxetine, gabapentin, guanfacine, ketoprofen, magnesium, mefenamic acid, metoprolol, nadolol, naproxen, nimodipine, verapamil, and vitamin B6.13

Topiramate was still under study when the guidelines were released and wasn’t approved by the US Food and Drug Administration for migraine prophylaxis until 2004. The 2000 guidelines are undergoing revision.

References